← Back to Search

N/A

Surgery for Early-Stage Breast Cancer

Phase 2
Waitlist Available
Led By Julia Wong, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The clinical extent of DCIS must be less than or equal to 2.5 cm
Patients must undergo a wide excision. A re-excision after the initial biopsy might be needed. Complete resection of the area of DCIS with a histologic margin of at least 1 cm must be achieved
Must not have
Patients with nipple discharge
Patients with a history of prior malignancies other than squamous or basal cell carcinoma of the skin, or carcinoma in situ of the cervix
Timeline
Screening 3 weeks
Treatment Varies
Follow Up tbd-survivorship
Awards & highlights
No Placebo-Only Group

Summary

This trial will help determine if surgery to remove the cancer is the only treatment needed for small, early-stage breast cancers.

Who is the study for?
This trial is for individuals with small, low-grade ductal carcinoma in situ (DCIS) of the breast, measuring less than or equal to 2.5 cm. Participants must have had a recent high-quality mammogram and undergone surgical removal with clear margins of at least 1 cm. They should not have invasive cancer, previous breast cancers, nipple discharge, or be on certain cancer treatments like chemotherapy.
What is being tested?
The study is testing if just surgically removing the affected tissue—wide excision—is enough treatment for grade 1 or 2 DCIS without additional therapies. The effectiveness will be observed over time after surgery to ensure all suspicious areas are removed.
What are the potential side effects?
Since this trial involves observation after surgery rather than drug intervention, side effects may include typical post-surgical complications such as pain at the incision site, infection risk, scarring and potential psychological impacts from monitoring without further immediate treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My DCIS is 2.5 cm or smaller.
Select...
I have had or will have surgery to remove a breast cancer area with clear margins.
Select...
I have had a detailed mammogram for suspicious breast calcifications.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am experiencing nipple discharge.
Select...
I have had cancer before, but it was not skin cancer or early-stage cervical cancer.
Select...
My cancer has spread to the lymph nodes in my armpit.
Select...
I have received chemotherapy or Tamoxifen as a follow-up treatment.
Select...
I have had breast cancer or DCIS in either breast before.
Select...
My cancer is invasive, possibly even at an early stage.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~tbd-survivorship
This trial's timeline: 3 weeks for screening, Varies for treatment, and tbd-survivorship for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To determine if patients with DCIS can be effectively treated with wide excision alone.
Secondary study objectives
Breast

Side effects data

From 2016 Phase 3 trial • 356 Patients • NCT00048997
31%
Fatigue (lethargy, malaise, asthenia)
23%
Alopecia
17%
Late RT Toxicity: Other: NOS
11%
Nausea
10%
Anorexia
9%
Late RT Toxicity: Brain: NOS
9%
Headache
7%
Late RT Toxicity: Skin: NOS
6%
Memory loss
1%
Dyspnea (shortness of breath)
1%
Hemorrhage-Other
1%
Ataxia (incoordination)
1%
Mood alteration-depression
1%
Pain-Other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Prophylactic Cranial Irradiation (PCI)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Observation (omission of RT)Experimental Treatment1 Intervention
Wide excision of DCIS; no radiotherapy (RT).

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,107 Previous Clinical Trials
356,979 Total Patients Enrolled
Brigham and Women's HospitalOTHER
1,664 Previous Clinical Trials
11,834,828 Total Patients Enrolled
Massachusetts General HospitalOTHER
3,006 Previous Clinical Trials
13,307,124 Total Patients Enrolled

Media Library

Wide Excision (N/A) Clinical Trial Eligibility Overview. Trial Name: NCT00165256 — Phase 2
Breast cancer Research Study Groups: Observation (omission of RT)
Breast cancer Clinical Trial 2023: Wide Excision Highlights & Side Effects. Trial Name: NCT00165256 — Phase 2
Wide Excision (N/A) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00165256 — Phase 2
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top